Huisheng Bio: Independent Director’s 2025 Annual Work Report (Wang Ming)

Wuhan Huisheng Biotechnology Co., Ltd.

2025 Independent Directors’ Work Report

(Wang Ming)

Dear shareholders and shareholder representatives:

As an independent director of Wuhan Huisheng Biotechnology Co., Ltd. (hereinafter referred to as the "Company"), in 2025, I strictly followed the "Company Law of the People's Republic of China", "Listed Company Governance Code", "Measures for the Administration of Independent Directors of Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies" (hereinafter referred to as "Self-Regulatory Supervision Guidelines No. 2") """) and other laws, regulations and relevant provisions of the "Articles of Association" and "Independent Director Work System", faithfully, diligently and independently perform their duties, give full play to the role of independent directors, and safeguard the legitimate rights and interests of the company and all shareholders, especially small and medium-sized shareholders. The performance report for 2025 is now as follows:

1. Basic situation

(1) Work history, professional background and part-time job status

I am Wang Ming, born in 1956, with Chinese nationality, no right of residence abroad, and a doctoral degree. Second-level professor at China Agricultural University, doctoral supervisor, retired. He once served as an independent director of Jinhe Biology (SZ.002688), vice president of the Chinese Veterinary Association, and editor-in-chief of "Chinese Veterinary Journal". He is currently the Chairman of the Board of Supervisors of the Chinese Veterinary Medical Association, a member of the Specialty Construction Committee of the Chinese Veterinary Medical Association, a deputy director of the Academic Committee of the Qinghai Provincial Key Laboratory of Animal Disease Pathogen Diagnosis and Green Prevention and Control Technology Research, a think tank expert of the First Pet Medicine Branch of the Chinese Veterinary Drug Association, and an expert of the Graduate Education Supervision Group of the Graduate School of China Agricultural University. He will serve as an independent director of the company from October 2025.

(2) Explanation of independence

During my tenure as an independent director of the company, I have not held any position in the company other than as an independent director, nor have I held any position in the company's major shareholder companies. I have no relationship with the company or major shareholders that would hinder my independent and objective judgment, and there are no circumstances that would affect the independence of independent directors. This is in compliance with the relevant requirements for the independence of independent directors in the "Administrative Measures for Independent Directors of Listed Companies" and "Self-Discipline Supervision Guidelines No. 2".

2. Annual performance overview of independent directors

(1) Information about the board of directors and shareholders’ meeting

During the reporting period, the company held a total of 8 board meetings. Among them, a total of 3 meetings were held during my term of office, and I attended all the meetings in person. There was no situation where I failed to attend the board of directors meetings in person for two consecutive times. Before each meeting of the board of directors, the secretary of the company's board of directors and the securities affairs department provided me with meeting materials and introduced relevant situations in accordance with the legal time. On the basis of carefully reading the meeting materials and in-depth understanding of the actual situation, I attended every meeting, carefully reviewed every resolution of the Board of Directors, and voted in favor without any objection or abstention.

During the reporting period, the company held a total of 4 shareholders' meetings, of which no shareholders' meeting was held during my term of office.

(2) Information about special committees of the board of directors

The company's board of directors consists of four special committees: Audit Committee, Remuneration and Assessment Committee, Nomination Committee, and Strategy Committee. As the chairman of the Nomination Committee, a member of the Audit Committee, a member of the Remuneration and Appraisal Committee, and a member of the Strategy Committee, I strictly follow the requirements of relevant laws, regulations and systems, conscientiously perform my duties, and safeguard the legitimate rights and interests of the company and shareholders.

During the reporting period, the Company’s Audit Committee held a total of 5 meetings. Among them, a total of 3 meetings were held during my term of office, and I attended all meetings in person, without being absent or entrusted to attend the meeting. The four proposals reviewed at the meeting, including the election of the chairman of the audit committee of the fourth session of the board of directors, the appointment of the company's financial director, the third quarter report for 2025, and the use of part of idle raised funds for cash management, were all passed without objection.

During the reporting period, the Company’s Nomination Committee held a total of 3 meetings. Among them, a total of 1 meeting was held during my term of office. I attended all meetings in person, and there was no case of absence or proxy attendance at the meeting. The meeting reviewed the proposal to appoint senior managers of the company, and I passed it without objection.

During the reporting period, the Company’s Remuneration and Assessment Committee held a total of 2 meetings, including 1 meeting during the term of office; the Company’s Strategy Committee held a total of 3 meetings, including 1 meeting during the term of office. I personally attended the above-mentioned meetings and reviewed and passed the motions involved in the meetings without objection.

(3) Work status of special meetings of independent directors

In 2025, a total of 2 special meetings of the company’s independent directors were held. During my term of office, the company did not hold a special meeting of independent directors.

(4) Communication status between internal audit institution and accounting firm

During the reporting period, I communicated with the accounting firm on the company's annual audit work arrangements and key tasks, and actively promoted the company's internal audit institution and accounting firm to play a role in the company's audit work.

(5) Communicating with small and medium-sized shareholders and safeguarding the legitimate rights and interests of investors

2025 During the year, I actively communicated with small and medium-sized shareholders to understand their demands and suggestions; for the relevant matters reviewed by the company's board of directors, I required the company to provide relevant information in advance for careful review, conduct timely investigations, inquire with relevant departments and personnel, etc., and use my professional knowledge to exercise voting rights independently, objectively and fairly, without being affected by the company and major shareholders. influence; actively study relevant laws, regulations and rules and regulations, deepen the knowledge and understanding of relevant laws and regulations, especially those related to regulating the company's corporate governance structure and protecting the rights and interests of public shareholders, understand the company's operation and management situation and other relevant information in the industry, provide better suggestions for the company's scientific decision-making and risk prevention, and effectively safeguard the legitimate interests of small and medium-sized shareholders.

(6) On-site work

In 2025, I used the opportunity to attend meetings of the board of directors and special committees and other appropriate times to conduct on-site work and inspections at the company to understand the company's operating conditions, financial conditions, internal control system construction and implementation, etc., and actively paid attention to the implementation of the company's information disclosure work, and the accumulated on-site working time complied with relevant regulations. At the same time, I actively communicated with the company's directors and management, and listened to their thoughts and opinions on the current operating situation, the progress of major events, the impact of external industry changes on the company, and the company's strategic development plan. Combining my own professional knowledge and insights, I put forward scientific and reasonable suggestions for the company's operation and management.

(7) The company’s cooperation with independent directors

In 2025, the company's board of directors, senior managers and staff of the securities affairs department can actively cooperate with me in performing my duties as an independent director, provide relevant meeting materials in strict accordance with relevant laws and regulations, normative documents and the company's internal rules, and assign dedicated personnel to be responsible for the organization of meetings and collection of signed documents, etc., to provide convenience for my work. The company has established smooth communication channels to ensure that I understand the company's operations and internal controls in a timely manner.

3. Key matters of independent directors’ annual performance of duties

During the reporting period, I focused on the following matters when performing my duties:

(1) Related transactions that should be disclosed

During my tenure, the company has not had any related party transactions that need to be disclosed to the outside world.

(2) Plans for the company and relevant parties to change or waive their commitments

After verification, all commitments made by the company and relevant parties were strictly observed, and there were no changes or exemptions to the commitments.

(3) Decisions made and measures taken by the board of directors of the acquired listed company regarding the acquisition

In 2025, the company has no acquisitions or acquisitions of listed companies.

(4) Regular reports and internal control evaluation reports

During the reporting period, the company strictly complied with the requirements of the Securities Law, Shenzhen Stock Exchange GEM Stock Listing Rules, Self-Regulatory Guidelines No. 2 and other laws and regulations, normative documents and the Articles of Association, and prepared and disclosed periodic reports and annual internal control evaluation reports on time. The content of the reports truly, accurately and completely reflected the actual situation of the company. All directors and senior managers of the company have signed written confirmation opinions on the periodic reports.

(5) Appointment of accounting firm

During my tenure, the company did not appoint an accounting firm.

(6) Changes in accounting policies, accounting estimates or correction of major accounting errors

During the reporting period, the company did not make any changes in accounting policies, accounting estimates or correction of major accounting errors due to reasons other than changes in accounting standards.

(7) Nominating directors and appointing senior managers

During the reporting period, the company completed the general election of the board of directors and the appointment of senior managers. The shareholders' meeting elected Mr. Zhang Weiyuan and Mr. Liu Zexiang as the company's directors, and Mr. Ran Mingdong and Mr. Wang Ming were the company's independent directors. The employees' congress elected Ms. Zhou Jian as the company's employee director. According to the company's internal management requirements, Mr. Han Jie was appointed as general manager, Mr. Yang Kaijie as deputy general manager and financial director, Mr. Huang Jinbin and Mr. Li Shuo as deputy general managers, and Mr. Wang Qingfeng as secretary of the board of directors. It is understood that the educational background, work experience and professional qualities of the directors and senior management personnel appointed this time are capable of fulfilling the responsibilities and requirements of the company's corresponding positions. The review and voting procedures for the election are legal and compliant, and there is no harm to the interests of the company and its shareholders, especially small and medium-sized shareholders.

(8) Remuneration of directors and senior managers, formulation or modification of equity incentive plans and employee stock ownership plans, incentive objects being granted rights and conditions for exercising rights and interests being met, directors and senior managers arranging shareholding plans in subsidiaries to be spun off

During my tenure, the company has not been involved in reviewing the remuneration of directors and senior managers, formulating or changing equity incentive plans, employee stock ownership plans, etc.; the company has not had any directors or senior managers arrange shareholding plans in subsidiaries to be spun off.

4. Overall evaluation and suggestions

I have served as an independent director of the company since October 16, 2025. During my term of office, I have adhered to the principle of diligence and responsibility, and conscientiously performed my duties as an independent director in accordance with relevant laws and regulations, normative documents, departmental rules and the "Articles of Association" and "Independent Director Work System", actively participated in the decision-making of the board of directors, prudently exercised the rights of independent directors, fully exerted my functions as an independent director, and promoted the company's steady development and standardized operations.

In 2026, I will continue to work diligently and responsibly, continuously strengthen the study of relevant laws, regulations and normative documents, pay closer attention to industry development and the company's operating conditions, strengthen communication with other directors and management, give full play to my professional advantages and supervisory role, promote the company's stable and standardized operations, continuously improve the level of corporate governance, and safeguard the legitimate rights and interests of investors, especially small and medium-sized shareholders.

Wuhan Huisheng Biotechnology Co., Ltd.

Independent Director: Wang Ming April 16, 2026